Mike currently serves as Chairman of the Board at Mirum Pharmaceuticals, Inc. and Plexium, Inc. and as Director of Horizon Therapeutics, plc., and BioMarin Pharmaceutical, Inc., in addition to Mirati. Prior to his appointment as chairman at Mirum Pharmaceuticals, he served as Executive Chairman from to 2019 and Chief Executive Officer from the company’s inception in 2018 to 2019.
Mike has served as Executive Chairman of Amplyx Pharmaceuticals, Inc, Reneo Pharmaceuticals, Inc., and Spruce Biosciences, Inc. since 2017. He has also served as President and Chief Executive Officer of Amplyx from 2015 to 2017, as Chairman and Chief Executive Officer of Reneo from 2014 to 2017, and as a venture partner at Pappas Ventures since 2010. He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a privately held biotechnology company, before it was acquired by Shire. In 2009, he served as President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company.
From 2005 until its acquisition in 2008, Mike was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from 2003 to 2005 and as Chief Business Officer from 2001 until 2003. Prior to joining SGX Pharmaceuticals, Inc., Mike acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. From 1994 to 1998, Mike was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mike served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. From 1974 to 1993, he served in various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development.
Mike received his B.S. in chemistry from the University of Nottingham in the United Kingdom.